Description du projet
Améliorer le diagnostic pourrait permettre de mieux comprendre la carence en vitamine D
De plus en plus de preuves étayent désormais le rôle important de la vitamine D dans les tissus extrasquelettiques et la manière dont l’insuffisance de vitamine D peut influencer des maladies comme le cancer et la maladie cardiovasculaire. En outre, les quantités nécessaires pour la santé sont probablement supérieures à celles que l’on croyait auparavant. Dans le même temps, l’insuffisance ou la carence en vitamine D est en hausse. Même si les estimations varient, les preuves suggèrent que plus d’un milliard de personnes dans le monde (plus de 10 % de la population) présentent une insuffisance ou une carence en vitamine D. OSAvit-D met au point un dispositif rentable de diagnostic sur le lieu d’intervention pour effectuer un dépistage à grande échelle lors des consultations externes et sur le terrain. Ce dispositif renforcera et permettra la détection et le traitement précoces d’une carence en vitamine D potentiellement néfaste et de plus en plus répandue.
Objectif
OSASEN is a young technological SME focused on the development of novel biosensors for healthcare (Point of Care-PoC devices), addressing priority needs in healthcare diagnostics and/or therapies monitoring for the benefit of patients, providing affordable systems with unique features that meet specific well identified requirements in healthcare. OSASEN has recently identified a healthcare need in relation with prevention, treatment and monitoring of Vitamin D (VitD) deficiency. VitD (1,25-DihydroxyvitaminD) is considered a multipurpose steroid hormone that in human plays an essential role in multiple aspects, being its primary role to participate in the regulation of metabolism of calcium and phosphorous. VitD deficiency is evident throughout the European population at a prevalence of 13% (FP7-613977-ODIN project), a rate that is a matter of concern. People over 50 have an increased risk of vitamin D deficiency with consequent bone loss risk leading to osteoporosis and fractures. Emerging evidence has shown that VitD administration improves muscle performance and reduces falls in VitD deficient older adults. Other populations of higher risk for VitD deficiency are children, pregnant and lactating women and patients with digestive disorders, among others. VitD deficiency is also associated with increased risk of cancer, cardiovascular disease, infections, and autoimmune diseases. For example, several studies have shown that VitD levels are lower in Multiple Sclerosis patients, and monitoring and VitD supplementation to them is highly recommended. In this context, OSASEN has identified the opportunity to develop a novel PoC device for the quantification of VitD in blood or urine based on lateral flow (LF) immunoassay, combined with electrochemical detection on screen printed electrodes (SPEs). For doing so, it is necessary to incorporate an expert in LF immunoassays and antibody selection, conjugation, handling & stabilization to OSASEN’s team.
Champ scientifique
- engineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsbiosensors
- medical and health sciencesbasic medicineneurologymultiple sclerosis
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesclinical medicineoncology
Programme(s)
Régime de financement
CSA - Coordination and support actionCoordinateur
48160 DERIO
Espagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.